Skip to main content
SpringerLink
Log in

Immunmodulatorische Therapie bei Autoimmunerkrankungen

Quo vadis?

Immunomodulatory therapy of autoimmune diseases

Quo vadis?

  • Leitthema
  • Published:
Der Ophthalmologe Aims and scope Submit manuscript

Zusammenfassung

Immunmodulatorische Therapien sind der Goldstandard in der Behandlung von Autoimmunerkrankungen. Ein immer besseres Verständnis der Mechanismen, die zum Auftreten von Autoimmunerkrankungen führen, ermöglicht neben den „Säulen“ wie den Glukokortikoiden und den Antimalariamitteln eine immer bessere und immer spezifischere Therapie. Dies bedeutet für unsere Patienten heutzutage eine große Chance, ihre Erkrankung adäquat behandeln zu können. Über die letzten Jahrzehnte hat sich diesbezüglich sehr viel getan, und die Entwicklung neuer Substanzen und Behandlungswege hält an. Diese Arbeit gibt einen Überblick über immunmodulatorische Therapieansätze.

Abstract

Immunomodulatory therapy is the gold standard in the treatment of autoimmune diseases. Increasing knowledge of the underlying mechanisms leading to autoimmunity enables patients to be treated with better and more specific therapies apart from the classical therapies, such as antimalarial drugs and glucocorticoids. For patients this nowadays means a great chance to receive optimized therapy. Numerous treatment options have been developed over the last decades and the development of new treatment approaches and strategies is still ongoing. This review gives an overview of immunomodulatory therapy approaches.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Behring E, Kitasato S (1890) On the development of immunity to diphtheria and tetanus in animals. Dtsch Med Wochenschr 16:1113

    Article  Google Scholar 

  2. Moen JK (1937) Tissue culture studies on bacterial hypersensitivity: iv. protective effect of immune plasma against the deleterious influence of streptococcal extract on hypersensitive cells. J Exp Med 65(4):587–594

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Cooper MD, Peterson RD, Good RA (1965) Delineation of the Thymic and Bursal Lymphoid Systems in the Chicken. Nature 205: p:143–146

    Article  Google Scholar 

  4. Fagraeus A (1947) Plasma cellular reaction and its relation to the formation of antibodies in vitro. Nature 159(4041):499

    Article  CAS  PubMed  Google Scholar 

  5. Hench PS et al (1949) The effect of a hormone of the adrenal cortex (17-hydroxy-11-dehydrocorticosterone: compound E) and of pituitary adrenocortical hormone in arthritis: preliminary report. Ann Rheum Dis 8(2):97–104

    Google Scholar 

  6. Dougherty TF, White A (1943) Influence of adrenal cortical secretion on blood elements. Science (80- ) 98(2547):367–369

    Article  CAS  Google Scholar 

  7. Hills AG, Forsham PH, Finch CA (1948) Changes in circulating leukocytes induced by the administration of pituitary adrenocorticotrophic hormone in man. Blood 3(7):755–768

    CAS  PubMed  Google Scholar 

  8. Gruneberg T (1951) Adrenocortical preparations in psoriasis. Dermatol Wochenschr 123(8):173–175

    CAS  PubMed  Google Scholar 

  9. Malbran JL (1950) Cortisone in ophthalmology; preliminary report. Prensa Med Argent 37(51):3113–3116

    CAS  PubMed  Google Scholar 

  10. Graham RO, Peyman GA (1974) Intravitreal injection of dexamethasone. Treatment of experimentally induced endophthalmitis. Arch Ophthalmol 92(2):149–154

    Article  CAS  PubMed  Google Scholar 

  11. Burmester GR (2001) Molecular mechanisms of action of gold in treatment of rheumatoid arthritis – an update. Z Rheumatol 60(3):167–173

    Article  CAS  PubMed  Google Scholar 

  12. Kalia S, Dutz JP (2007) New concepts in antimalarial use and mode of action in dermatology. Dermatol Ther 20(4):160–174

    Article  PubMed  Google Scholar 

  13. Ben-Zvi I et al (2012) Hydroxychloroquine: from malaria to autoimmunity. Clin Rev Allergy Immunol 42(2):145–153

    Article  CAS  PubMed  Google Scholar 

  14. Borel JF et al (1976) Biological effects of cyclosporin A: a new antilymphocytic agent. Agents Actions 6(4):468–475

    Article  CAS  PubMed  Google Scholar 

  15. Paavonen T et al (1981) Effect of cyclosporin A on in vitro proliferative activity and immunoglobulin synthesis of isolated human lymphoid cell subpopulations. Clin Exp Immunol 43(2):342–350

    CAS  PubMed  PubMed Central  Google Scholar 

  16. Masuda K et al (1989) Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behcet’s disease. Lancet 1(8647):1093–1096

    Article  CAS  PubMed  Google Scholar 

  17. Alpsoy E, Akman A (2009) Behcet’s disease: an algorithmic approach to its treatment. Arch Dermatol Res 301(10):693–702

    Article  PubMed  Google Scholar 

  18. Mitrevski M et al (2015) Intravenous Immunoglobulin and Immunomodulation of B‑Cell – in vitro and in vivo Effects. Front Immunol 6: p:4

    Google Scholar 

  19. Ballow M (2014) Mechanisms of immune regulation by IVIG. Curr Opin Allergy Clin Immunol 14(6):509–515

    Article  CAS  PubMed  Google Scholar 

  20. Schwab I, Nimmerjahn F (2013) Intravenous immunoglobulin therapy: how does IgG modulate the immune system? Nat Rev Immunol 13(3):176–189

    Article  CAS  PubMed  Google Scholar 

  21. Tellier Z (2005) Intravenous immunoglobulin in eye involvement. Clin Rev Allergy Immunol 29(3):295–306

    Article  CAS  PubMed  Google Scholar 

  22. Mili-Boussen I et al (2015) Azathioprine for cortico-resistant noninfectious uveitis. Tunis Med 93(3):158–163

    PubMed  Google Scholar 

  23. Zannin ME et al (2013) Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1‑year followup data from the Italian registry. J Rheumatol 40(1):74–79

    Article  CAS  PubMed  Google Scholar 

  24. Tappeiner C et al (2012) Is tocilizumab an effective option for treatment of refractory uveitis associated with juvenile idiopathic arthritis? J Rheumatol 39(6):1294–1295

    Article  PubMed  Google Scholar 

  25. Angeles-Han S, Flynn T, Lehman T (2008) Abatacept for refractory juvenile idiopathic arthritis-associated uveitis- a case report. J Rheumatol 35(9):1897–1898

    PubMed  Google Scholar 

  26. Joshi L et al (2015) Long-term outcomes of Rituximab therapy in ocular Granulomatosis with polyangiitis: impact on localized and nonlocalized disease. Ophthalmology 122(6):1262–1268

    Article  PubMed  Google Scholar 

  27. Glass LR, Freitag SK (2015) Management of orbital IgG4-related disease. Curr Opin Ophthalmol 26(6):491–497

    Article  PubMed  Google Scholar 

  28. Huang JF et al (2012) Immunomodulatory effect of the topical ophthalmic Janus kinase inhibitor tofacitinib (CP-690,550) in patients with dry eye disease. Ophthalmology 119(7):e43–50

    Article  PubMed  Google Scholar 

  29. Bajpai M (2009) Fostamatinib, a Syk inhibitor prodrug for the treatment of inflammatory diseases. IDrugs 12(3):174–185

    CAS  PubMed  Google Scholar 

  30. Kong Y et al (2007) RNA interference as a novel and powerful tool in immunopharmacological research. Int Immunopharmacol 7(4):417–426

    Article  CAS  PubMed  Google Scholar 

  31. Hoyer BF et al (2004) Short-lived plasmablasts and long-lived plasma cells contribute to chronic humoral autoimmunity in NZB/W mice. J Exp Med 199(11):1577–1584

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Hoyer BF et al (2008) How to cope with pathogenic long-lived plasma cells in autoimmune diseases. Ann Rheum Dis 67(Suppl 3):iii87–iii89

    Article  PubMed  Google Scholar 

  33. Neubert K et al (2008) The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med 14(7):748–755

    Article  CAS  PubMed  Google Scholar 

  34. Taddeo A et al (2015) Long-lived plasma cells are early and constantly generated in New Zealand Black/New Zealand White F1 mice and their therapeutic depletion requires a combined targeting of autoreactive plasma cells and their precursors. Arthritis Res Ther 17:39

    Article  PubMed  PubMed Central  Google Scholar 

  35. Furie R et al (2011) A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 63(12):3918–3930

    Article  CAS  PubMed  Google Scholar 

  36. Taddeo A et al (2015) Selection and depletion of plasma cells based on the specificity of the secreted antibody. Eur J Immunol 45(1):317–319

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Med. Klinik m.Sp. Rheumatologie und klin. Immunologie, Charité Universitätsmedizin Berlin/Deutsches Rheumaforschungszentrum, Charitéplatz 1, 10117, Berlin, Deutschland

    B. F. Hoyer &  F. Hiepe

Authors
  1. B. F. Hoyer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F. Hiepe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to B. F. Hoyer.

Ethics declarations

Interessenkonflikt

B.F. Hoyer und F. Hiepe geben an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hoyer, B.F., Hiepe, F. Immunmodulatorische Therapie bei Autoimmunerkrankungen. Ophthalmologe 113, 373–379 (2016). https://doi.org/10.1007/s00347-016-0263-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00347-016-0263-3

Schlüsselwörter

Keywords

Search

Navigation